Monoclonal Antibody Treatment
**NOTE**
Jackson Purchase Medical Center is aware that the Food and Drug Administration (FDA) has halted the use of two COVID-19 monoclonal antibody therapies because newly released data indicates that they are not effective against the Omicron variant. These include Lilly’s bamlanivimab plus etesevimab and Regeneron’s casirivimab plus imdevimab. We previously offered casirivimab plus imdevimab at our hospital but are no longer providing this treatment given that it is no longer authorized for use at this time.
|
Important facts about bamlanivimab and etesevimab
For information on the authorized use of bamlanivimab and etesevimab and mandatory requirements under the Emergency Use Authorization, please review:
Fact Sheet for Patients, Parents and Caregivers (English)
Fact Sheet for Patients, Parents and Caregivers (Spanish)
Important facts about casirivimab and imdevimab
For information on the authorized use of casirivimab and imdevimab and mandatory requirements under the Emergency Use Authorization, please review:
Fact Sheet for Patients, Parents and Caregivers (English)
Fact Sheet for Patients Parents and Caregivers (Spanish)